MyFinsight
Home
Blog
About
Contact
Download
Download image
Net proceeds from
issuance of shares in 2024...
$427,783
Net proceeds from
the exercise of...
$2,063
Cash provided by
financing activities
$404,321
Effect of exchange rate
changes
$24,589
Accounts payable and
other current...
$531,767
Canceled cashflow
$25,525
Net decrease in
cash, cash...
-$4,298,617
Canceled cashflow
$428,910
Stock-based compensation
expense
$403,509
Other non-cash items
-$230,462
Total changes in
operating assets and...
-$225,931
Depreciation and
amortization
$21,303
Canceled cashflow
$305,836
Payments of current
portion of long-term...
$25,525
Cash used in
operating activities
-$4,727,527
Canceled cashflow
$881,205
Prepaid expenses and
other current assets
$278,213
Defined benefit pension
plan
-$26,710
Long term deposit and
other noncurrent...
$913
Net loss
-$5,608,732
Back
Back
Cash Flow
Gain Therapeutics, Inc. (GANX)
Gain Therapeutics, Inc. (GANX)
source: myfinsight.com